Shots:
- Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platform
- Furthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disorders
- Upon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and commercialize identified small-molecule compounds, and Reborna will be eligible to receive an upfront payment, research funding, milestone payments tied to research, development, and sales achievements, and tiered royalties on net sales
Ref: Ono | Image: Ono & Reborna Biosciences
Related News:- Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
